Efficacy of Tulisokibart in Managing Moderate-to-Severe Ulcerative Colitis
|
Reviewed & Translated by Dat Tien Nguyen, B.A, ScM.
|
Posted on November 4th, 2024
|
Recent studies on the pathophysiology of ulcerative colitis has found that human tumor necrosis factor–like cytokine 1A (TL1A) plays an important role in exacerbating the condition. The cytokine can interact with DR3 receptors on helper T cells to amplify type 1 and type 17 inflammation. Tulisokibart is an antibody that can bind to TL1A, and Merck had recently sponsored a study to assess its ability to manage ulcerative colitis.
The phase 2 clinical trial involved 210 participants with moderate-to-severe ulcerative colitis, who had an average modified Mayo score of around 7. These patients had previously been treated with glucocorticoids, immunosuppressants, and other therapies but had not achieved remission. Subjective assessment using the Inflammatory Bowel Disease Questionnaire (IBDQ) yielded an average score of 115 out of 224. Baseline biochemical analysis showed an average C-reactive protein level of 10 mg/L and fecal calprotectin level of 1200 μg/g. Participants were randomly assigned to receive either a placebo or tulisokibart. Tulisokibart was administered intravenously with an initial dose of 1000 mg on day one, followed by 500 mg at weeks 2, 6, and 10. By week 12, biopsy showed that 32% of those treated with tulisokibart achieved clinical remission, compared to only 11% in the placebo group. Tulisokibart also showed superiority in improving IBDQ scores and reducing inflammation markers such as C-reactive protein and fecal calprotein. The authors suggested that future studies should include a larger cohort and a longer observation period for more conclusive results.
The phase 2 clinical trial involved 210 participants with moderate-to-severe ulcerative colitis, who had an average modified Mayo score of around 7. These patients had previously been treated with glucocorticoids, immunosuppressants, and other therapies but had not achieved remission. Subjective assessment using the Inflammatory Bowel Disease Questionnaire (IBDQ) yielded an average score of 115 out of 224. Baseline biochemical analysis showed an average C-reactive protein level of 10 mg/L and fecal calprotectin level of 1200 μg/g. Participants were randomly assigned to receive either a placebo or tulisokibart. Tulisokibart was administered intravenously with an initial dose of 1000 mg on day one, followed by 500 mg at weeks 2, 6, and 10. By week 12, biopsy showed that 32% of those treated with tulisokibart achieved clinical remission, compared to only 11% in the placebo group. Tulisokibart also showed superiority in improving IBDQ scores and reducing inflammation markers such as C-reactive protein and fecal calprotein. The authors suggested that future studies should include a larger cohort and a longer observation period for more conclusive results.